


Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-444US1	Application No. 10/533,613
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.96(b))		Applicant Richard G. Vile et al.	
		Filing Date January 30, 2006	Group Art Unit 1633

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/KH/	AC	WO 00/14255	03/16/00	WIPO				
/KH/	AD	WO 01/21823	03/29/01	WIPO				
	AE							
	AF							
	AG							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/KH/	AH	Hallenbeck et al., "A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular Carcinoma," <u>Human Gene Therapy</u> , 1999, 10:1721-1733
↓	AI	Maity and Solomon, "Both Increased Stability and Transcription Contribute to the Induction of the Urokinase Plasminogen Activator Receptor (uPAR) Message by Hypoxia," <u>Exp. Cell Res.</u> , 2000, 255:250-257
	AJ	Wang et al., "Posttranscriptional regulation of urokinase plasminogen activator receptor messenger RNA levels by leukocyte integrin engagement," <u>Proc. Natl. Acad. Sci. USA</u> , 1998, 95:6296-6301
	AK	

Examiner Signature /Kelaginamane Hiriyanal/	Date Considered 05/14/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	